Understanding primary pulmonary hypertension

Critical Care Nursing Quarterly

Volumn 26, Issue 1, 2003, Pages 28-34

  Berkowitz, Diane Schleyer ^a   Coyne, Nancy Grimes ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Atrial septostomy; Nitric oxide; Primary pulmonary hypertension; Pulmonary pressure; Receptor antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANGELICA SINENSIS EXTRACT; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; DECONGESTIVE AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; EPHEDRA EXTRACT; FUROSEMIDE; GARLIC EXTRACT; GINSENG EXTRACT; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; METOLAZONE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PARACETAMOL; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTACYCLIN RECEPTOR ANTAGONIST; PROSTAGLANDIN G2; SILDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

ADULT; AGE; ANTICOAGULATION; ARTERY BLOOD FLOW; ARTICLE; BALLOON DILATATION; BLEEDING; CASE REPORT; CLINICAL FEATURE; DYSPEPSIA; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; GENE THERAPY; HEART ATRIUM SEPTUM; HEART CATHETERIZATION; HEART PALPITATION; HUMAN; LEG EDEMA; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; NURSING; OXYGEN THERAPY; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REBOUND; SODIUM RESTRICTION; SURVIVAL TIME; SYMPTOM; SYNCOPE; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT INDICATION;

EID: 0037232215     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200301000-00005     Document Type: Article

References (19)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111-117.
2. Rubin LJ. Primary pulmonary hypertension: accp consensus statement. Chest. 1993;104:236-250.
3. Rich S, ed. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998; September 6-10 1998; Evan, France. Retrieved from www.who.int/ncdcvd/pph.html.
4. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719-725.
5. McLaughlin V, Shillington A, Rich S. Survival primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
6. Voelkel NF, Tuder RM, Weir KE. Pathophysiology of primary pulmonary hypertension: from physiology to molecular mechanisms In: Rubin LJ, Rich S, eds. Primary Pulmonary Hypertension. New York: Marcel Dekker; 1997:83-129.
7. Newman JH. Treatment of primary pulmonary hypertension-the next generation. N Engl J Med. 2002;346(12):933-935.
8. Rubin LJ. Pulmonary hypertension. In: Foster V, Alexander RW, Orourke RA, eds. Hurst's The Heart. New York: McGraw-Hill; 2001:1607-1623.
9. Georgiou D, Brundage BH. Pulmonary hypertension In: Klower RA, ed. The Guide to Cardiology. Greenwich, Connecticut; LeJacq Communications, Inc; 1995:607-625.
10. D'Alonzo GE, Dantzker DR. Diagnosing primary pulmonary hypertension In: Rubin LJ, Rich S, eds. Primary Pulmonary Hypertension. New York: Marcel Decker; 1997:227-252.
11. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107(2):216-23.
12. DeBacker TLM, Smedema JP, Carlier SG. Current management of primary pulmonary hypertension. Bio-Drugs. 2001;15(12):801-817.
13. Nauser T, Stiles S. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician. 2001;63(9):1789-1798.
14. Frazier S. Diagnosing and treating primary pulmonary hypertension. The Nurse Pract. 1999;24(9):18-38.
15. Chatterjee K, DeMarco T, Alpert J. Pulmonary hypertension: hemodynamic diagnosis and management. Arch Intern Med. 2002;162(17):1925-1933.
16. Flolan [package insert]. Glaxo Wellcome, Research Triangle Park, North Carolina; 1995.
17. Bosentan(Tracleer™) [manufacture information]. Actelin Pharmaceuticals, Inc, San Francisco, CA; 2002.
18. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. JACC. August, 1998:297-304.
19. Consensus Statements. Recommendations on over-the-counter medications in patients with pulmonary arterial hypertension. Available at http://www. phassociation.org/learn/consensus_statements/recommendations-on-cc-m